tbuckley/cabot-search huggingface dataset:
Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention
Authors: Safi U. Khan, Mohammed Osman, Muhammad U. Khan, Muhammad Shahzeb Khan, Di Zhao, Mamas A. Mamas, Nazir Savji, Ahmad Al-Abdouh, Rani K. Hasan, Erin D. Michos
Journal: Annals of Internal Medicine (2020)

The safety and effectiveness of dual therapy (direct oral anticoagulant [DOAC] plus P2Y12 inhibitor) versus triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) is unclear.To examine the effects of dual versus triple therapy on bleeding and ischemic outcomes in adults with AF after PCI.Searches of PubMed, EMBASE, and the Cochrane Library (inception to 31 December 2019) and ClinicalTrials.gov (7 January 2020) without language restrictions; journal Web sites; and reference lists.Randomized controlled trials that compared the effects of dual versus triple therapy on bleeding, mortality, and ischemic events in adults with AF after PCI.Two independent investigators abstracted data, assessed the quality of evidence, and rated the certainty of evidence.Four trials encompassing 7953 patients were selected. At the median follow-up of 1 year, high-certainty evidence showed that dual therapy was associated with reduced risk for major bleeding compared with triple therapy (risk difference [RD], -0.013 [95% CI, -0.025 to -0.002]). Low-certainty evidence showed inconclusive effects of dual versus triple therapy on risks for all-cause mortality (RD, 0.004 [CI, -0.010 to 0.017]), cardiovascular mortality (RD, 0.001 [CI, -0.011 to 0.013]), myocardial infarction (RD, 0.003 [CI, -0.010 to 0.017]), stent thrombosis (RD, 0.003 [CI, -0.005 to 0.010]), and stroke (RD, -0.003 [CI, -0.010 to 0.005]). The upper bounds of the CIs for these effects were compatible with possible increased risks with dual therapy.Heterogeneity of study designs, dosages of DOACs, and types of P2Y12 inhibitors.In adults with AF after PCI, dual therapy reduces risk for bleeding compared with triple therapy, whereas its effects on risks for death and ischemic end points are still unclear.None.
NATIONAL TRENDS IN READMISSION RATES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT VERSUS SURGICAL AORTIC VALVE REPLACEMENT WITH SEVERE AORTIC STENOSIS
Authors: Nagarjuna Gujjula, Raviteja Guddeti, Dixitha Anugula, Ryan Walters, Arun Kanmanthareddy
Journal: Journal of the American College of Cardiology (2020)
In vitro chemoresponse assay results and population clinical response rates in women with ovarian cancer.
Authors: Scott Daniel Richard, Candace McClure, Charles A. Leath, Thomas J. Herzog, Christine M. Gan, Thomas C. Krivak, Michael Cibull, Robert L. Coleman
Journal: Journal of Clinical Oncology (2012)

e15578 Background: While platinum-based chemotherapies have been identified as the most effective agents in ovarian cancer, they are not effective in all women. An in vitro assay that determines whether platinum agents are likely to be effective for individual patients could have clinical utility. This study determines whether in vitro platinum sensitivity rates are similar to published population response rates for ovarian cancer and examines differences in platinum sensitivity across histologic subtypes. Methods: In vitro chemoresponse testing (ChemoFx, Precision Therapeutics, Pittsburgh, PA) was performed on tumors from 3,130 patients with primary or recurrent epithelial ovarian cancers. Histologic subtypes included serous, endometrioid, clear cell, and mucinous. Primary cancers, stages II-IV, were examined. Tumors were classified as responsive (R), intermediately responsive (IR), or non-responsive (NR) to chemotherapy. The rates of pan-resistance (Pan R), defined as non-responsive to all agents tested, was also examined in both primary and recurrent tumors. Statistical analyses were conducted using the Chi-square test with Bonferroni correction where appropriate. Results: Of 3,130 eligible patients, 2,335 had stage II-IV primary tumors (75%); the remaining 795 (25%) were recurrent. Overall, 77% of primary tumors were responsive (R or IR) to combination carboplatin/paclitaxel (CP). CP response rate was significantly different across histologic subtypes (p&lt;0.001), with serous tumors exhibiting the highest response rate (79%). CP response was significantly greater in serous tumors (79%) when compared to mucinous tumors (65%; p=0.03). CP response was significantly greater in primary tumors (77%) when compared to recurrent tumors (65%)(p&lt;0.001). In addition, the rate of pan R was significantly greater in recurrent tumors (26%) compared to primary tumors (15%)(p&lt;0.001). Conclusions: ChemoFx response rates to PC are consistent with expected population response rates. As anticipated, more aggressive histologic subtypes were less responsive to CP in vitro. These data suggest that the ChemoFx assay provides tumor-specific information that may assist in chemotherapy decision making.
TRANSITIONAL CARE EFFECTIVENESS: 10-YEAR RESULTS FROM THE ‘BRIDGING THE DISCHARGE GAP EFFECTIVELY’ (BRIDGE) PROGRAM TO IMPROVE OUTCOMES FOR CARDIAC PATIENTS
Authors: Joshua Garfein, Eva M. Kline-Rogers, George Cholack, Rachel Krallman, Delaney Feldeisen, Daniel Montgomery, Kim Eagle, Melvyn Rubenfire, Sherry Bumpus
Journal: Journal of the American College of Cardiology (2020)
TESTOSTERONE AND EARLY ISCHEMIC HEART DISEASE
Authors: Abdul Haseeb, Raza Mian, Muhammad Bilal, Sharath Rajagopalan, Hamza Hafeez, Najam Saqib, Mirza Mujadil Ahmad, Muhammad Siddique Pir, Sangeeta Prabhakar Bhat, Nicholas Ierovante
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF LEFT VENTRICULAR EJECTION FRACTION USING TEICHHOLZFORMULA FOR ACUTE HEART FAILURE IN PATIENTS WITH TAKOTSUBO SYNDROME
Authors: Yoshimitsu Takaoka, Tsutomu Yoshikawa, Masafumi Ono, Kenshiro Arao, Toshiaki Isogai, Yoichi Imori, Tatsuya Onuki, Akihisa Kimura, Konomi Sakata, Kunihiko Teraoka, Hiroki Mochizuki, Tetsuo Yamaguchi, Takeshi Yamamoto, Nagao Ken, Morimasa Takayama
Journal: Journal of the American College of Cardiology (2020)
WAIT FOR IT: IMMUNE CHECKPOINT INHIBITOR ASSOCIATED COMPLETE HEART BLOCK WITH RECOVERY OF AV CONDUCTION AFTER TREATMENT WITH STEROIDS
Authors: Amy Riviere, Jay Shah, Laura Onderko, Sanjeev Francis, Patrick Hohl, Samuel Tristram Coffin, Brooke Ritvo, Andrew Corsello, Jessica Kvasic
Journal: Journal of the American College of Cardiology (2020)
Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer.
Authors: Caroline Diorio, Julie Lemieux, Marc-Andre Cote, Louise Provencher, Corinne Nadeau-Larochelle, Simon Jacob, Eric Demers, Rosemarie Tremblay-Lemay, Christine Saint-Pierre, Michel Beauchemin, Frederic Barabe, Christian Laflamme
Journal: Journal of Clinical Oncology (2012)

634 Background: Trastuzumab is well tolerated without major side effects except for cardiac toxicity. Although a number of clinical parameters have been associated with trastuzumab-associated cardiac toxicity (TACT), there is some indication that genetic variation of the HER2 gene may play a toxic role in a population of metastatic breast cancer patients. However, this finding needs confirmation and we looked at a population of non-metastatic breast cancer. This study aimed to evaluate the association between cardiac toxicity and HER2 [Ile655Val] polymorphism in non-metastatic breast cancer patients treated with trastuzumab. Methods: The Ile655Val HER2 polymorphism was assessed in 73 women using TaqMan technology. For this study, the genotyping was performed using DNA extracted from normal breast tissue located at more than 1 cm of any other lesions. Charts review was used to collect information on TACT which was defined as any decline in LVEF &gt; 10 % from the baseline to &lt; 55 % or a decline in LVEF &gt; 5 % to &lt; 50 % (lower limit of normal). The Fisher exact test was used to evaluate the association between cardiac toxicity and HER2 polymorphism. Results: No deviation from the Hardy-Weinberg equilibrium has been observed for the allele and genotype frequencies. The distribution of HER2 polymorphism was 3 Val/Val (4%), 18 Ile/Val (25%) and 52 Ile/Ile (71%). In this population, 19% (14/73) developed a cardiac toxicity. We found that 29% (6/21) of Ile/Val or Val/Val carriers compared to 15% (8/52) of Ile/Ile carriers showed TACT, but this association did not reach statistical significance (P = 0.21). Conclusions: HER2 Ile655Val polymorphism may be an efficient marker of TACT considering this tendency with this small cohort of patients. Larger sample is needed to strengthen this conclusion, since this result may influence on prescribing decision for adjuvant chemotherapy and anti-HER2 therapy in HER2 positive patients.
Effect of suppression of bcl-2 with antisense oligonucleotides on p53 expression.
Authors: Patrick Guinan, Marvin Rubenstein, Courtney M.P. Hollowell
Journal: Journal of Clinical Oncology (2013)

e16085 Background: In theory gene therapy is specific but difficulties are encounted in practice. Tumors express altered patterns of expression and regulatory pathways provide many targets. However the actual activity of most genes are similar to normal. Resistance develops because pathways are complex, regulated by stimulatory and inhibitory factors, each affected by therapy. Tumors alter dependence on targeted gene products for growth by relying upon others, through compensation. Antisense oligos have targeted regulatory proteins in both in vivo and in vitro prostate cancer models. Cells treated with antisense directed against bcl-2 compensated by suppressing caspase-3 (an apoptosis promoter) and enhancing androgen receptor (AR), (co-activating) p300 and IL-6 expression. This suggests that in LNCaP a progression to increased androgen sensitivity accompanies bcl-2 suppression with a pattern of co-activation associated with more advanced prostate tumors. Methods: We evaluated mono- and bispecific oligos which targeted and equally suppressed bcl-2 expression in LNCaP cells. To further evaluate compensatory mechanisms related to tumor resistance we evaluated the level of the suppressor gene p53 employing RT-PCR and agarose gel quantification. Bands representing pcr product were photographed, converted to black and white and assessed by MIPAV software. Results: Comparable amounts of RNA from LNCaP cells treated with either mono- or bispecific oligos directed against bcl-2 (and EGFR in the bispecifics) were evaluated by RT-PCR using primers directed against p53. When background intensity was subtracted, the relative intensity of all bands corresponding to p53 and representing cells treated with MR 4 , MR 24 and MR 42 (compared to controls) were respectively increased 47.5% ± 42.3 (p = 0.02), 86.5% ± 35.3 (p = 0.00013) and 58.0% ± 42.0 (p = 0.0077). These results were pooled from both duplicate PCR runs and gels, and indicate each oligo targeting bcl-2 significantly enhanced p53 expression. Conclusions: Inhibition of bcl-2 activity mediated via antisense oligos enhances suppressor gene p53 expression. In contrast to the effects noted above, p53 enhancement would appear beneficial.
Laparoscopic repeat surgery for gastro-oesophageal reflux disease: Results of the analyses of a cohort study of 117 patients from a multicenter experience
Authors: Fabrizio Panaro, Piera Leon, Thierry Perniceni, Giorgio Bianchi, Francois-Regis Souche, Jean Michel Fabre, Vito De Blasi, Santiago Azagra, Grégory Marin, Giusy Giannandrea, Brice Gayet, Francis Navarro, David Fuks
Journal: International Journal of Surgery (2020)
EMERGENT BALLOON VALVULOPLASTY TO TREAT CARDIOGENIC SHOCK FROM SEVERE AORTIC STENOSIS AND CORONARY THROMBOSIS
Authors: Miranda Merrill, Howard Song, Harsh Golwala, Gurion Lantz, Katherine Rajotte, Stephanie Khouw, Ryle Przybylowicz, Scott M. Chadderdon, Firas Zahr
Journal: Journal of the American College of Cardiology (2020)
Identification of estrogenically synthesized LRP16 as an ERα coactivator and its role in ERα-positive breast cancer
Authors: W. Han, Y. Zhao, Z. Wu, Y. Mu, L. Yu, Y. Meng, K. Huang, L. Zang, Q. Li
Journal: Journal of Clinical Oncology (2006)

10676 Background: Aberrant ERα activity is linked to genesis and malignant progression of breast cancer through direct target gene activation or repression. A complex network of coregulatory proteins is largely believed to determine the transcriptional activity of ERα. LRP16 was identified previously to be an estrogen (E2) responsive gene, but its function involving in conferring estrogen signalling pathway is not clear. Methods: Endogenous LRP16 expression in MCF-7 cells was stably suppressed by retrovirus-mediated small interference RNA (siRNA). The effects of LRP16 expression on E2-stimulated growth and invasive ability of MCF-7 cells were determined in vitro and in vivo assays. The effects of LRP16 expression on ERα transactivation were determined by luciferase assays. The interaction of LRP16 and ERα was examined by GST pull-down and coimmunopricipitation (CoIP) assays. Northern blot and Western blot were used to detect the mRNA and protein levels of ER target genes in LRP16-inhibited MCF-7 cells. The LRP16 expression levels in primary breast cancer were detected by Northern blot. Results: Fristly, LRP16 expression was characterized to be dependent on estrogen activities. Then, LRP16 was identified to be an estrogen-independent ERα cofactor in ER-positive breast cancer cells and demonstrate that LRP16 is an essential coactivator to ERα-mediated transactivation in an estrogen-dependent manner. Suppression of LRP16 expression in ER-positive breast cancer cells specifically inhibits the transcription of ER upregulated genes, results in the increase of E-cadherin expression through ER mediation. In vitro and in vivo data demonstrate that suppression of LRP16 inhibits the ability of estrogen-stimulated proliferation and invasiveness of ER-positive breast cancer cells. The pathological and clinical characteristics of human breast cancer includining ER/PR-positiveness, tumor diameter and the involvement of axillary lymphoid nodes were tightly linked with the LRP16 gene expression level. Conclusions: These results establish a mechanistic link between estrogen receptor status, its coactivator LRP16, and progression of ER-positive breast cancers, and may provide a novel antiestrogenic target for the therapy of ER positive breast cancer. No significant financial relationships to disclose.
WIDE COMPLEX TACHYCARDIA DUE TO ACCESSORY PATHWAY RESEMBLING OUTFLOW TRACT VT ABLATED AT THE CORONARY CUSPS: DIAGNOSTIC DILEMMAS AT AN UNUSUAL LOCATION
Authors: Nachiket Madhav Apte, Lance Longmore, Madhu Reddy, Seth H. Sheldon
Journal: Journal of the American College of Cardiology (2020)
30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer
Authors: A. Gkountakos, M. Simbolo, C. Vicentini, R.T. Lawlor, L. Veghini, S. Pilotto, V. Ludovini, R. Chiari, S. Novello, G. Tortora, M. Milella, A. Scarpa, V. Corbo, E. Bria
Journal: Annals of Oncology (2020)
Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC)
Authors: O. Stoss, P. Albers, M. Werther, D. Zielinsky, N. Jost, J. Rueschoff, T. Henkel
Journal: Journal of Clinical Oncology (2006)

4641 Background: Patients with metastatic carcinoma of the prostate (CaP) develop after a mean of 15 months resistance to hormone ablation therapy. However, the underlying molecular mechanisms are still unknown. Our goal was to identify the transcriptional changes that are characteristic for the transition to hormone resistant prostate cancer (HRPC) using oligonucleotide microarrays. Here, we report the attempt to profile fresh frozen tissue obtained by palliative transurethral resection (TUR) in patients with HRPC and concomittant urinary obstruction. Methods: Indications for palliative TUR were locally progressive tumors with obstruction and voiding problems. HRPC was defined according to the criteria of Scher et al. 1995. Samples of 8 HRPC patients were compared to tissues from 8 hormone-sensitive CaP patients including biological and technical replicates. All tissue samples had been pathologically evaluated. Only macrodissected prostate samples with at least 70% tumor content were used for RNA extraction. RNA quality was controlled using the Bioanalyzer Nanochip (Agilent Technologies, Palo Alto). Expression analysis was performed on Affymetrix oligonucleotide arrays. Results: We identified 323 genes being significantly deregulated (corrected p-value &lt;0.05, false discovery rate &lt;0.05). These genes were mapped to cellular pathways using the KEGG annotation and the most significantly deregulated pathways were identified. Deregulation of metabolic pathways included fatty acid metabolism as well as oxidative phosphorylation and ATP synthesis. Cell cycle control seems to be further suppressed by the downregulation of JNK-pathway via MEKK4 and JUND, the downregulation of p21 (CDKN1A) and the induction of Cylcin D1. We also present evidence for a significant downregulation of actin cyctoskeleton components. Deregulated genes likely to be specific for the transition from prostate carcinoma to HRPC will be presented. Conclusions: Gene expression profiling has been successfully standardised using fresh TUR material of HRPC patients. Deregulated genes have been mapped to specific signal transduction pathways. On this platform, clinical trials in patients with HRPC using specific inhibitors of cell signalling are being developed. [Table: see text]
EFFECT OF EXERCISE TRAINING ON PLATELET AGGREGATION AND ON P2Y12 INHIBITOR RESISTANCE AFTER MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL
Authors: Talia Dalçóquio, Remo Holanda de Mendonça Furtado, Flavia Bittar Britto Britto Arantes, Mayara Alves dos Santos, Leandro Silva Alves, Maria Urbana Pinto Brandão Rondon, Larissa Ferreira-Santos, Maria Janieire de Nazaré Nunes Alves, Aline Gehlen Ferrari, Paulo Rizzo Genestreti, Luciano Moreira Baracioli, André Franci, Rocio Salsoso, Carlos Eduardo Negrão, José Carlos Nicolau
Journal: Journal of the American College of Cardiology (2020)
A Nationwide Survey of Adult T-Cell Leukemia/Lymphoma (ATL) Newly Diagnosed Over the Last Decade in Japan
Authors: H. Katsuya, K. Ishitsuka, A. Utsunomiya, S. Hanada, T. Eto, Y. Moriuchi, Y. Saburi, T. Yamanaka, J. Suzumiya, K. Tamura
Journal: Annals of Oncology (2012)
Efficacy of treatment of vulva cancer patients and analysis of their hormonal status.
Authors: Galina A. Nerodo, Ekaterina Nerodo
Journal: Journal of Clinical Oncology (2012)

e21127 Background: hormonodependency of vulva is wellknown. This broughtusto study hormonal status of vulva cancer patients depending on treatment efficacy Methods: we present comparative analysis of hormonal status of vulva cancer patients in two groups: group 1 (50 patients) without relapse of the disease in 5-year period, and group 2 (35 patients) with relapse developed within the first year. Blood concentrations of testosterone, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone were determined in all patients under study by means of radiometric methods. Estrone, estradiol, estriol with subsequent calculation of their sum were determined in daily urine by Brown method. Results: In the presence of effect (group 1) initial total amount of estrogens was twice as large than in its absence. In group 1 estradiol concentration exceeded the corresponding parameter of group 2 by three times(7.6±0.6 &amp; 1,4±0.3,p&lt;0.001). The amount of secreting estriol at positive result was almost twice higher than in cases of absence of the effect(10.02±1.7 &amp; 4.6±0.49, p&lt;0.001). The groups differed by secretion levels of follicle-stimulating and luteinizing hormones. Blood concentration of these hormones was lower in negative results that in positive. Distinct differences were also observed in progesterone and prolactin levels. In the group with positive result of treatment progesterone concentration was much higher than in the group without treatment effect. On the contrary, prolactin concentration in group 1 was significantly less than in group 2. The highest degree of reliability of quantitative indices related to treatment efficacy was observed for progesterone. Positive result of corresponding treatment may be predicted at normal initial progesterone level, and negative result at its low level (3-4 times lower than the norm). Another parameter - blood concentration of prolactin - can be used almost with the same degree of reliability. Conclusions: results of the study allow to suggest an existence of interrelation between treatment efficacy of vulva cancer patients and functional activity of hypophysis-gonadal system. Some of its parameters may be used to predict results of complex treatment of vulva cancer patients.
Baby-step chemotherapy as a way to deliver chemotherapy in poor PS small cell lung cancer.
Authors: Vanita Noronha, Vijay Patil, Amit Joshi, Vamshi Muddu, Kumar Prabhash
Journal: Journal of Clinical Oncology (2012)

e17500 Background: Majority of patients with SCLC present with advanced stage and poor ECOG performance status. Hence delivery of adequate dose of chemotherapy is compromised. We hypothesized that initial low-dose chemotherapy might improve PS and enable administration of standard-dose chemotherapy, thus extending benefit of chemotherapy to otherwise ineligible patients. Methods: 30 patients with ECOG performance status 2-4 received low-dose chemotherapy consisting of either single agent carboplatin at AUC 2 or an abbreviated course of platinum-etoposide. Patients whose PS improved got full-dose chemotherapy with the standard regimen of platinum-etoposide. Demographic details, toxicity, time to progression and overall survival were analyzed. Univariate and multivariate analysis was performed to determine factors associated with TTP and OS. Results: Median age was 58 years with male predominance. The PS was IV in 9, III in 20 and II in 1 patient. Extensive-stage and limited-stage disease was seen in 24 and 6 patients respectively.15 patients received single-agent carboplatin, 10 patients abbreviated cisplatin-etoposide, 1 patient each cyclophosphamide and cisplatin-etoposide and 3 patients refused chemotherapy. Major grade 3-4 toxicity was mucositis in 1, loose motions in 1 and hyponatremia in 4 patients. There was no grade 3- 4 haematological toxicity. The median number of dose-reduced cycles was 1 and 3 patients received more than 2 cycles. 22 patients were eligible and willing for full-dose chemotherapy. The median time to start of full-dose chemotherapy was 11.5 days (4-26 days). The median number of cycles of standard-dose chemotherapy was 5 (1-6) with 16 completing planned schedule. Grade 3-4 toxicity was neutropenia in 50%, febrile neutropenia in 25%, loose motions in 25% and hyponatremia in 40%. The overall TTP and OS was 182 days and 263 days respectively. Presence of SIADH (p = 0.02) and completion of standard treatment (p = 0.001) had a positive impact on TTP while completion of treatment (p = 0.01) and normal LDH (p = 0.03) had a positive impact on OS. Conclusions: Low-dose chemotherapy is well-tolerated and might help in extending the benefit of standard-dose chemotherapy to otherwise ineligible patients.
HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer
Authors: Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, Sumesh Kachroo
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer" published on 20 Mar 2020 by National Comprehensive Cancer Network.